Skip to main content
SpringerLink
Log in

Clinical pharmacology in normal volunteers of praziquantel, a new drug against schistosomes and cestodes

An example of a complex study covering both tolerance and pharmacokinetics

  • Originals
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Summary

The tolerance of Praziquantel (2-cyclohexylcarbonyl-1, 3, 4, 6, 7, 11b-hexahydro-2H-pyrazino-[2, 1-a]isoquinoline-4-one) in oral doses of 1×20 mg/kg, 1×50 mg/kg, 3×10 mg/kg and 3×25 mg/kg body weight (τ=4 h) was tested in a complex study involving 36 healthy volunteers. In addition to the usual assessment of clinical chemistry, haematology, coagulation physiology, urinalysis, clinico-physiological examination including EEG, and medical examination, clinico-psychological parameters were also recorded and special neurological investigations were performed. No clinically relevant changes were found in any of the laboratory parameters, nor in the medical-neurological or clinico-physiological examinations. Based on a few clinicopsychological parameters and subjective comments, the largest daily dose tested (3×25 mg/kg=75 mg/kg) produced a slight, transient disturbance in general well-being, which was barely detectable on objective clinical examination. The pharmacokinetic behaviour was dominated by rapid metabolism and pronounced first-pass metabolism of praziquantel, which greatly limits the value of results obtained by GC analysis of unchanged drug in serum. The peak concentration in serum was reached after 1– h, and the elimination half-life for the period 2–8 h was 1–1.5 h.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Andrews, P., Gönnert, R., Pohlke, R., Seubert, J.: Praziquantel — Ein neues Schistosomenmittel. Tropenmed. Parasitol.28, 275 (1977)

    Google Scholar 

  2. Seubert, J., Pohlke, R., Loebich, F.: Synthesis and properties of praziquantel, a novel broad spectrum anthelmintic with excellent activity against Schistosomes and Cestodes. Experientia33, 1036 (1977)

    Google Scholar 

  3. Thomas, H., Andrews, P.: Neuere Ergebnisse zur Wirksamkeit und Wirkungsweise von Praziquantel bei Cestoden. Tropenmed. Parasitol.28, 275 (1977)

    Google Scholar 

  4. Gemmell, M. A., Johnstone, P. D., Oudemans, G.: The effect of Praziquantel on Echinococcus granulosus, Taenia hydatigena and Taenia ovis in dogs. Res. Vet. Sci.23, 121–123 (1977)

    Google Scholar 

  5. Gönnert, R., Andrews, P.: Praziquantel, a new broad spectrum antischistosomal agent. Z. Parasitenkd.52, 129–150 (1977)

    Google Scholar 

  6. James, C., Webbe, G., Nelson, G. S.: The susceptibility to Praziquantel of Schistosoma haematobium in the baboon and of S. japonicum in the vervet monkey. Z. Parasitenkd.52, 179–194 (1977)

    Google Scholar 

  7. Thomas, H., Gönnert, R., Pohlke, R., Seubert, J.: Investigations about treatment of larval cestodes. 7th Int. Conf. on Pathophysiol. of Parasitic Infections, Thessaloniki 1975

  8. Bylund, G., Bang, B., Wikgren, K.: Experimental Evaluation of the Effect of Praziquantel against Diphyllobothrium latum in vivo and in vitro. Bol. Chil. Parasitol.32, 7–10 (1977)

    Google Scholar 

  9. Thomas, H., Gönnert, R., Pohlke, R., Seubert, J.: A new compound against adult tapeworms. 7th Int. Conf. on Pathophysiol. of Parasitic Infections, Thessaloniki 1975

  10. Thomas, H., Gönnert, R.: The efficacy of Praziquantel against cestodes in cats, dogs and sheep. Res. Vet. Sci.24, 20–25 (1978)

    Google Scholar 

  11. Thomas, H., Gönnert, R.: The efficacy of Praziquantel against cestodes in animals. Z. Parasitenkd.52, 117–127 (1977)

    Google Scholar 

  12. Webbe, G., James, C.: A comparison of the susceptibility of Praziquantel of Schistosoma haematobium, S. Japonicum, S. mansoni, S. intercalatum and S. mattheei in hamsters. Z. Parasitenkd.52, 169–177 (1977)

    Google Scholar 

  13. Webbe, G., James, C.: Praziquantel: The efficacy against Schistosoma haematobium and S. japonicum in hamsters and monkeys. Tropenmed. Parasitol.28, 275–276 (1977)

    Google Scholar 

  14. Thomas, H.: Experimental results with EMBAY 8440 in Cestodiasis and Cyxticercus. Bol. Chil. Parasitol.32, 2–6 (1977)

    Google Scholar 

  15. Baldock, F. C., Flucke, W. J., Hopkins, T. J.: Efficiency of Praziquantel, a new cestocide, against Taenia hydatigena in the dog. Res. Vet. Sci.23, 237–238 (1977)

    Google Scholar 

  16. Pellegrino, J., Lima-Costa, F. F., Carlos, M. A., Mello, R. T.: Experimental chemotherapy of Schistosomiasis mansoni. XIII-Activity of Praziquantel, an isoquinoline-pyrazino-derivate, on mice, hamsters and Cebus monkeys. Z. Parasitenkd.52, 151–168 (1977)

    Google Scholar 

  17. Andrews, P., Diekmann, H. W., Eberstein, M. v., Frohberg, H., Gröning, P., Mürmann, P.: Toxicological, pharmacological and pharmacokinetic studies with a new cestocide. 7th Int. Conf. on Pathophysiol. of Parasitic Infections, Thessaloniki 1975

  18. Diekmann, H. W., Andrews, P., Eberstein, M. v., Frohberg, H., Gröning, P.: Toxicological, pharmacological and pharmacokinetic studies with a new anthelmintic: 2nd Europ. Multicolloquy of Parasitol., Trogir 1975

  19. Thomas, H., Gönnert, R.: The Efficacy of Praziquantel against Cestodes in Animals. Z. Parasitenk.52, 117–127 (1977)

    Google Scholar 

  20. Mürmann, P., Eberstein, M. v., Frohberg, H.: Zur Verträglichkeit von Praziquantel. Vet. med. Nachr.2/76, 142–153 (1976)

    Google Scholar 

  21. Steiner, K., Garbe, A., Diekmann, H. W., Nowak, H.: The fate of Praziquantel in the organism. I. Pharmacokinetics in animals. Eur. J. Drug Metabol. Pharmacokinetics1, 85–95 (1976)

    Google Scholar 

  22. Steiner, K. Garbe, A.: The fate of Praziquantel in the organism. II. Distribution in rats. Eur. J. Drug Metabol. Pharmacokinetics1, 97–106 (1976)

    Google Scholar 

  23. Diekmann, H. W., Bühring, K. U.: The fate of Praziquantel in the organism. III. Metabolism in rat, beagle dog and rhesus monkey. Eur. J. Drug Metabol. Pharmacokinetics1, 107–112 (1976)

    Google Scholar 

  24. Andrews, P.: Pharmacokinetic studies with Praziquantel in animals using a biological assay. Vet. med. Nachr.2/76, 154–165 (1976)

    Google Scholar 

  25. Documenta GEIGY: Wissenschaftliche Tabellen (Scientific tables), 7th ed., 1st revised reprint, p. 701. Basel: Geigy 1969

    Google Scholar 

  26. The Human Pharmacology Center. Darmstadt, Germany E. Merck 1976

  27. Deklaration von Helsinki, verabschiedet von der XVIII. Generalversammlung des Weltärztebundes (WMA) 1964 in Helsinki (= Anlage 2 der Bekanntmachung der Richtlinien über die Prüfung von Arzneimitteln, 11.6. 1971, Bundesanzeiger Nr. 113, 25.6. 1971, S. 3

  28. Richtlinien der Bundesärztekammer für statistische Qualitätskontrolle und Ringversuche, I und II Deutsches Ärzteblatt68, 2228–2231 (1971);71, 959–965 (1974)

  29. Mummenthaler, M.: Neurologischer Untersuchungskurs. Deutsches Ärzteblatt71, 3392–3397, 3463–3476, 3551–3558 (1974);72, 79–88, 145–150, 270–273 (1975)

    Google Scholar 

  30. Janke, W., Lehmann, E.: Experimental investigations on the psychological action of EMD 16923 (2, 5 and 10 mg) under 3 different experimental conditions. On file at E. Merck, Darmstadt, Germany

  31. Janke, W., Debus, G.: Double blind psychometric evaluation of Pimacide and Haloperidol versus Placebo in emotionally labile volunteers under two different workload conditions. Pharmakopsychiatrie1, 34–51 (1972)

    Google Scholar 

  32. Diekmann, H. W.: Quantitative determination of Praziquantel in body fluids by gas liquid chromatography. To be published in Eur. J. Drug Metab. Pharmacokinetics (1978)

  33. EMD 29810 — Human pharmacology. Study of the acute tolerance of EMBAY 8440 in oral doses of 1 × 20 mg/kg, 3 × 10 mg/kg, 1 × 50 mg/kg and 3 × 25 mg/kg in healthy, male subjects. On file at E. Merck, Darmstadt

  34. EMBAY 8440 — Human pharmacokinetics after oral administration in the dosages of 1 × 5 mg/kg, 1 × 10 mg/kg, 1 × 20 mg/kg, 1 × 50 mg/kg, 3 × 10 mg/kg and 3 × 25 mg/kg (GC analysis). On file at E. Merck, Darmstadt

  35. EMBAY 8440 — Human pharmacokinetics after oral administration of 3 × 20 mg/kg to healthy, male subjects. On file at E. Merck, Darmstadt

  36. Davies, A.: Initial experiences with EMBAY 8440 in the treatment of Human Infections due to Schistosoma Haematobium. Meeting of the Associations of German-speaking Specialists in Tropical Medicine in Lindau 1977

  37. Schenone, H., Galdames, M., Rivadeneira, A., Morales, E., Hoffman, M. T., Asalgado, N., Meneses, G., Mora, M. V., Cabrera, G.: Treatment of Hymenolepis nana Infection in Children by a Single oral Dose of Praziquantel (EMBAY 8440). Bol. Chil. Parasitol.32, 11–13 (1977)

    Google Scholar 

  38. Paz, G.: Treatment of Taeniasis saginata with Praziquantel (EMBAY 8440). Bol. Chil. Parasitol.32, 14–16 (1977)

    Google Scholar 

  39. Groll, E.: General Scope of Treatment with Praziquantel (EMBAY 8440) in Human Cestode Infections. Bol. Chil. Parasitol.32, 27–31 (1977)

    Google Scholar 

  40. Baranski, M. C.: Treatment of Human Taeniasis and Hymenolepiasis with Praziquantel (EMBAY 8440). Bol. Chil. Parasitol.32, 37–39 (1977)

    Google Scholar 

  41. Espejo, H.: Treatment of Infections by Hymenolepis nana, Taenia saginata, Taenis sollum and Diphyllobothrium pacificum with Praziquantel (EMBAY 8440). Bol. Chil. Parasitol.32, 39–40 (1977)

    Google Scholar 

  42. Canzonieri, C. J., Rodriguez, R. R., Castillo, E. E., de Balella, C. I., Lucena, M.: Therapeutic Trial with Praziquantel in Taenia saginata and Hymenolepis nana Infections. Bol. Chil. Parasitol.32, 41–42 (1977)

    Google Scholar 

  43. Apajalahti, J.: Treatment of Diphyllobotrium latum Infections with a Single Oral Dose of Praziquantel. Bol. Chil. Parasitol.32, 43 (1977)

    Google Scholar 

  44. Bühring, K. U., Diekmann, H. W., Garbe, A., Nowak, H.: Metabolism of Praziquantel in man. To be published in Eur. J. Drug Metab. Pharmacokinetics (1978)

  45. Patzschke, K., Pütter, J., Wegener, L. A., Horster, F. A., Diekmann, H. W.: Serum concentrations and renal excretion after oral application of C-14-Praziquantel to volunteers. Comparison between three determination methods. Eur. J. Drug Metab. Pharmacokinetics, in press (1978)

  46. Pütter, J., Held, F.: EMBAY 8440: Levels in blood plasma and milk of breastfeeding women. To be published

Download references

Author information

Authors and Affiliations

  1. Medical Research Division, E. Merck, Darmstadt, Federal Republic of Germany

    G. Leopold, W. Ungethüm, E. Groll, H. W. Diekmann & H. Nowak

  2. Medical Department, Bayer AG, Wuppertal, Federal Republic of Germany

    D. H. G. Wegner

Authors
  1. G. Leopold
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. W. Ungethüm
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. E. Groll
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. H. W. Diekmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. H. Nowak
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. D. H. G. Wegner
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Leopold, G., Ungethüm, W., Groll, E. et al. Clinical pharmacology in normal volunteers of praziquantel, a new drug against schistosomes and cestodes. Eur J Clin Pharmacol 14, 281–291 (1978). https://doi.org/10.1007/BF00560463

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00560463

Key words

Search

Navigation